stopped seizure AL = acute leukemia mixed lineage; ALL = acute lymphocytic leukemia; BMT = bone marrow transplantation; CML = chronic myelogenous leukemia; CMV = cytomegalovirus; CSF = cerebrospinal fluid; CsA = cyclosporin; GCV = ganciclovir; ND = not done; UPN = unique patient number. CsA level was assayed using the whole blood Tdx method. brain stem was not identified. Follow-up MRI scan 2 Discussion months later showed complete resolution of these abnormalities.
CsA is a common cause of encephalopathy and seizures in BMT patients. 2 Most often the encephalopathy is nonspeObjective eye movement abnormality with diplopia did not recur in three of the patients after CsA and GCV were cific and MRI scans of the head are negative, but sometimes CsA causes transient visual loss associated with MRI T2 re-introduced. In patient 1, diplopia recurred 5 days after restarting GCV and CsA and again resolved when both abnormalities primarily in the white matter of the occipital lobes. 3, 4 The MRI abnormalities are thought to be from drugs were withheld. The patient was then started on CsA alone with no recurrence of her eye movement disorder. ischemia or edema, and similar lesions from vasospasm have been reported in hypertensive encephalopathy and Patients 1 and 2 are alive now 24 and 72 months, respectively, after BMT; patients 3 and 4 died 69 days and 50 eclampsia. Less common presentations of CsA neurotoxicity are dysphasia and memory or personality changes. There months after BMT. On follow-up, myasthenia gravis did not develop in any of the four patients.
are also reports of rapidly evolving pyramidal, vestibular, or cerebellar dysfunction attributed to CsA and also reports when CsA alone was restarted (patient 1). We have not seen eye movement problems in transplant patients on CsA of spinal cord syndromes with paraparesis and a sensory alone, and there are no reports of eye movement abnormalilevel. 5, 6 Complete neurological and MRI recovery is the ties in nontransplant patients receiving GCV for CMV retirule and neurological recurrences generally do not take nitis. Although neither etiology, nor pathogenesis is known, place when CsA is re-instituted. There are also reports of these cases are important in showing that eye movement myopathy from CsA, with clinical improvement on dose abnormalities in transplant patients can be caused by toxreduction noted in one patient. 7 icity and do not necessarily indicate disease recurrence or The basis of CsA neurotoxicity is uncertain. A predicta CNS mass lesion. able correlation of neurotoxicity with CsA blood level has not been found. Many patients with CsA neurotoxicity have hypomagnesemia (including patients 1 and 2 in this report,
